112.59 0.00 (0.00%)
After hours: 4:57PM EST
|Bid||97.47 x 800|
|Ask||112.47 x 800|
|Day's Range||111.49 - 112.85|
|52 Week Range||82.59 - 113.00|
|Beta (5Y Monthly)||0.92|
|PE Ratio (TTM)||17.94|
|Earnings Date||Apr 20, 2020 - Apr 26, 2020|
|Forward Dividend & Yield||2.24 (1.98%)|
|Ex-Dividend Date||Apr 05, 2020|
|1y Target Est||111.73|
Investors in Quest Diagnostics Incorporated (NYSE:DGX) had a good week, as its shares rose 2.7% to close at US$111...
Chevron, Alaska Air, and Juniper Networks were some of the other companies that declared dividend increases in a busy week for such announcements.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 29) 10X Genomics Inc (NASDAQ: TXG ) Agile Therapeutics ...
Today we'll take a closer look at Quest Diagnostics Incorporated (NYSE:DGX) from a dividend investor's perspective...
Quest Diagnostics (DGX) -- which provides diagnostic testing for patients -- is our latest breakout stock, observes technical expert Leo Fasciocco, editor of Ticker Tape Digest.
Just-released numbers out of the North Carolina Department of Justice show a record number of data breaches in the state in 2019. The breaches, according to NCDOJ, impacted nearly 1.1 million North Carolinians, a 45 percent decrease from the 1.9 million impacted in 2018. Public records, released at the request of the Triangle Business Journal, highlight the biggest breaches: Jambav, doing business as ToonDoo.com: The comic strip creation website said an estimated 300,654 North Carolinians were impacted, according to what the company told the state.
Memorial Hermann Health System, the Houston area's largest health care system, will sell its outreach laboratory division to a major diagnostics company.
The acquisition is a step forward in Quest Diagnostics' (DGX) commitment toward offering high-quality, cost-efficient diagnostic services in Texas,especially the Houston metropolitan area.
Quest Diagnostics (NYSE: DGX), the leading provider of diagnostic information services, and Memorial Hermann Health System, a leading not-for-profit health system that includes 17 hospitals and more than 300 care delivery sites in the Greater Houston region, today announced a multi-pronged, long-term collaboration intended to broaden access to innovative, high-value laboratory services for providers and patients in Greater Houston.
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics' (DGX) acquisition of Clinical Laboratory Services of Boston Clinical Laboratories is expected to have been accretive to its Q4 earnings.
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has acquired Blueprint Genetics in an all-cash equity transaction. Blueprint Genetics is a leading specialty genetic testing company with deep expertise in gene variant interpretation based on next generation sequencing (NGS) and proprietary bioinformatics. Together, Quest and Blueprint Genetics will broaden access to actionable insights in genetic and rare diseases, improving patient care and pharmaceutical drug research and development. Financial terms of the transaction were not disclosed.
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has been selected as one of FORTUNE's World's Most Admired Companies in 2020 for the sixth consecutive year.
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2019 results on Thursday, January 30, 2020, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
Today we'll look at Quest Diagnostics Incorporated (NYSE:DGX) and reflect on its potential as an investment. To be...
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 38th Annual J. P. Morgan Healthcare Conference in San Francisco. Steve Rusckowski, Chairman, President and CEO and Mark Guinan, Executive Vice President and CFO will discuss the company's vision, goals and two-point strategy to accelerate growth and drive operational excellence. The presentation is scheduled for Tuesday, January 14, 2020 at 7:30 p.m. Eastern Time. Mr. Rusckowski and Mr. Guinan also will participate in a Q&A; session moderated by the host analyst.
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
In 2012 Steve Rusckowski was appointed CEO of Quest Diagnostics Incorporated (NYSE:DGX). This analysis aims first to...